Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-13-005175
Filing Date
2013-09-18
Accepted
2013-09-18 17:49:48
Documents
1
Period of Report
2013-09-16

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f3091613kaushik_actinium.html 3  
1 OWNERSHIP DOCUMENT f3091613kaushik_actinium.xml 3 2411
  Complete submission text file 0001213900-13-005175.txt   3856
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 6770 Blank Checks

Mailing Address 250 PHILLIPS BLVD SUITE 290 EWING NJ 08618
Business Address
DAVE KAUSHIK J (Reporting) CIK: 0001522751 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-52446 | Film No.: 131104285